CA-VEEVA-SYSTEMS
4.2.2021 13:05:06 CET | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life sciences industry. All of the top 7 CROs, except IQVIA, which has decided not to join the program at this time, are now able to leverage Veeva Vault CDMS capabilities to modernize clinical data management and build high-quality studies faster.
The growth of Veeva’s CRO partner program is enabling an industrywide shift to a modern clinical data management platform that better meets the needs of today’s clinical trials. Now 6 out of the top 7 global CROs have access to the support and training needed to build and execute studies with Veeva. As the need to run faster and more efficient trials grows, CROs are using Veeva's advanced technology to help sponsors improve trial performance.
“Veeva is enabling CROs to work more effectively with sponsors during the build process to accelerate trial starts,” said Henry Levy, general manager of Veeva Vault CDMS. “Our CRO partners are leading the way towards faster, more collaborative studies and continued excellence in trials.”
Vault CDMS is a modern cloud application suite that combines electronic data capture (EDC) , coding , data cleaning , and reporting . Customers are able to build study databases in six weeks or less and make mid-study amendments with zero downtime, freeing customers to run the trials they want without technology limitations.
Emerging biotechs are benefitting from the growing number of CROs adopting Vault CDMS. The access to a modern clinical data management solution provides them with the speed and nimbleness to accelerate clinical research.
The six global CROs joining Veeva’s partner program are Covance, ICON, Parexel, PPD, PRA Health Sciences, and Syneos Health. For CROs interested in learning more about the program, contact info@veeva.com .
What CROs are saying about Veeva Vault CDMS:
“ICON supports clients to accelerate clinical development and advance healthcare through applied technology,” said Lalit Pai, senior vice president, biometrics at ICON . “Veeva’s innovative clinical data management platform is enabling us to manage and deliver seamless integration for our clients and meet rigorous, global quality standards.”
“Veeva has an outstanding reputation in the industry and within our organization, as we have widely adopted many of its other platforms,” said Simon Fleming, vice president, data management at Parexel . “Veeva Vault CDMS provides us with an exciting opportunity to further build on our relationship and provide customers with more choice and flexibility.”
“PPD continues to expand our technology offerings focused on providing accelerated decision-making for our customers,” said Rob Petrie, senior vice president and chief technology officer at PPD . “The implementation of Veeva Vault CDMS provides PPD the flexibility to continue to provide innovative technologies, furthering PPD’s mission of bending the time and cost curve of drug development and enabling our clinical research teams to continue to raise the bar by providing the highest level of service and quality to our customers.”
“Veeva Vault CDMS is a valuable addition to our existing biometrics technology offerings and will provide our clients and partners with a greater choice,” said Michael Goedde, vice president, global data operations at PRA Health Sciences . “Veeva has been a respected and valued partner of ours for many years, and now we will be able to further enhance our clinical data management services as the drug development industry evolves.”
“At Syneos Health, our focus has always been on running clinical trials in the most efficient and integrated manner, and with the highest quality processes and procedures,” said Paul Colvin, president, clinical solutions at Syneos Health . “Our long-standing relationship with Veeva, combined with Veeva Vault CDMS, will allow us to accelerate our operational capabilities and work more collaboratively with our clients.”
Additional Information
For more on Veeva Vault CDMS, visit: veeva.com/CDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2021 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005394/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom